Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006365 · ClinicalTrials.gov registry record · Phase 2

External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer

A Phase 2 study of Prostate Cancer, sponsored by Radiation Therapy Oncology Group.

Completed
Registry status
Phase 2
Development phase
138
Enrollment target
20
Study locations

NCT00006365: Completed Phase 2 study of Prostate Cancer, sponsored by Radiation Therapy Oncology Group.

NCT00006365 is a Phase 2 study of Prostate Cancer that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 138 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006365, a Phase 2 study of Prostate Cancer, has completed, sponsored by Radiation Therapy Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
138 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of external-beam radiation therapy followed by implanted radiation therapy in treating patients who have prostate cancer.

Primary Outcome

Rate of late severe GU and GI toxicity defined as grade 3-5 GU and GI toxicity based on Common Toxicity Criteria 2.0

Conditions Studied

Interventions

  • RADIATION radiation therapy
  • RADIATION brachytherapy
  • RADIATION iodine I 125

Study Locations (20)

California

  • Mount Diablo Medical Center - Concord
  • Cancer Center and Beckman Research Institute, City of Hope - Duarte
  • California Cancer Center - Fresno
  • Saint Agnes Cancer Center - Fresno
  • Glendale Memorial Hospital and Health Center - Glendale
  • Sutter Health West Cancer Research Group - Greenbrae
  • University of California San Diego Cancer Center - La Jolla
  • Loma Linda University Medical Center - Loma Linda
  • Veterans Affairs Medical Center - Long Beach - Long Beach
  • USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
  • Jonsson Comprehensive Cancer Center, UCLA - Los Angeles

Alabama

  • University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
  • Huntsville Hospital System - Huntsville
  • Comprehensive Cancer Institute of Huntsville - Huntsville
  • MBCCOP - Gulf Coast - Mobile
  • Alabama Oncology, LLC - Montgomery
  • Radiation Oncology Associates of West Alabama - Tuscaloosa

Alaska

  • Providence Alaska Medical Center - Anchorage

Arizona

  • Arizona Cancer Center - Tucson

Arkansas

  • University of Arkansas for Medical Sciences - Little Rock

Trial Details

FieldValue
Enrollment Target 138 participants
Start Date 2000-11
Est. Completion 2013-11
Phase Phase 2
Radiation Therapy Oncology Group

144 total trials

What the finished NCT00006365 record still lists

NCT00006365 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (77% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which radiation therapy is the first listed.

NCT00006365 names 20 study sites across 5 states, led by California, Alabama, Alaska.

Frequently Asked Questions

What is clinical trial NCT00006365 about?

NCT00006365 is a clinical study titled "External-Beam Radiation Therapy Plus Implanted Radiation Therapy in Treating Patients With Prostate Cancer". RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Giving radiation therapy in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of external-beam radiation therapy followed by implanted radiation therapy in treati...

What is the current status of trial NCT00006365?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2000-11. Estimated completion is 2013-11.

What conditions does trial NCT00006365 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT00006365?

The interventions under investigation include: radiation therapy (RADIATION), brachytherapy (RADIATION), iodine I 125 (RADIATION).

Who is sponsoring clinical trial NCT00006365?

This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006365 being conducted?

This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00006365's enrollment target sits among peer trials

138 282nd of 735 higher than 454 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04402788 · 138 participants · Phase 2

    Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

  • NCT04883255 · 138 participants · Early Phase 1

    Cannabis Use, Cognition, and the Endocannabinoid System in HIV

  • NCT05620784 · 138 participants · Phase 3

    Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

  • NCT05832086 · 138 participants · Phase 2

    Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00006365, the US trial registry maintained by the National Library of Medicine. NCT00006365 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.